Farmak JSC extended its product line with Lipster, a new brand product for treatment of labial and facial herpes. The medicinal product is manufactured in 5% cream (5 mg) dosage form.
Lipster is a renewed and improved form of Acyclovir cream manufactured by Farmak JSC. The new drug is highly effective against Herpes Virus Type I and II.
Ivan Artemenko, Product Manager, Farmak JSC, says, “Every fifth person worldwide gets cold sore 2 to 10 times a year. And only 5% of people have resistance to Herpes Virus Type I and the reasons for such resistance have not been discovered yet.
And now we have Lipster, a drug, which will help the patients to control that common infection confidently. Lipster quickly inhibits the activity of herpes and efficiently removes external signs of the infection.
It is worth mentioning that Lipster combats herpes both at the disease onset (recommended for disease prevention and treatment) and at later stages (when papules and blisters appear and the diseased is suffering from the developing infection).
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...